Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
6
self-reported 2–10 band
Founded
2011
15 years
Legal entities
1
ABR
Office countries
1
1 address
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
SEMENTIS LIMITED
ABN36138550811
Legal entities
Show as table · Sementis Ltd: 1 registry entity
| SEMENTIS LIMITED | ABN 36138550811 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Sementis Ltd is an Australian unlisted public biotechnology company based in Adelaide, South Australia and dedicated to research and development of new vaccines to tackle viruses and diseases globally.
Sementis conducts it's research and development activities in partnership with the University of South Australia.
We are using our proprietary Sementis Copenhagen Vector (SCV) and associated manufacturing system for the rapid development of effective vaccines to tackle infectious diseases of highest unmet medical needs as well as vaccines for pandemic preparedness. Our vaccine technology is also under evaluation for the prevention of allergies, with potential future applications also in cancer.
Our lead vaccine candidates including a combination Zika-Chikungunya vaccine, a 'second generation' COVID-19 vaccine and therapeutic vaccine for peanut allergy.
The SCV system couples a genetically engineered, non-replicative viral vector with a genetically engineered commercial manufacturing cell-line. The genes of disease antigens can be easily added to the viral vector, allowing for rapid adaptation of the vaccine against a single or multiple diseases and then manufacture on a commercial scale.
The SCV is derived from a vaccinia virus strain used to eradicate smallpox, and concerns about safety have been addressed through our targeted genetic attenuation, thus making SCV vectored vaccines safe for use. Vaccines made using SCV are grown in our proprietary Chinese Hamster Ovary (CHO) cells, an industry standard cell line for large scale manufacturing with high yield and consistent batch quality.
Extensive advanced pre-clinical studies have shown that vaccines using the SCV platform are safe and efficacious after a single vaccination, eliciting potent T and B-cell immunity, and long lasting protective vaccine immune response. We are now focussed on final GLP toxicology and immunogenicity studies in preparation for first in-human Phase I clinical trials.
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | AU |
All codes: AU
Addresses
- AU25 North Terrace; Hackney, South Australia 5069Primary
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
3 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
Which legal entity operates under Sementis Ltd?
One South Australia entity on the ABR: SEMENTIS LIMITED (ABN 36 138 550 811), high confidence.
How many people work at Sementis Ltd?
6 counted staff profiles at January 2026, inside the self-reported 2–10 band.
Where does Sementis Ltd have offices?
One address on record, Australia only. Primary: 25 North Terrace, Hackney, South Australia 5069.
Has Sementis Ltd raised funding?
None linked to this brand.
Which companies are listed alongside Sementis Ltd?
10 profiles list Sementis Ltd as a peer — 82nd percentile in Biotechnology Research. It lists ten peers of its own. GroPep® Bioreagents Pty Ltd and Vaxine Pty Ltd list it back.